Scott W. Simpkins

Scott W. Simpkins

Auto-generated profile, based on publicly available information

Scott W. Simpkins

Octant Inc., Emeryville, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2017 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
JPJeff S Piotrowski
Jeff S Piotrowski
SLSheena C Li
Sheena C Li
RDRaamesh Deshpande
Raamesh Deshpande
SSScott W Simpkins
Scott W Simpkins
JNJustin Nelson
Justin Nelson
CBCharles Boone
Charles Boone

1 July 2021 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
JBJoshua S. Bloom
Joshua S. Bloom
LSLaila Sathe
Laila Sathe
CMChetan Munugala
Chetan Munugala
EJEric M. Jones
Eric M. Jones
MGMolly Gasperini
Molly Gasperini
VAValerie A. Arboleda
Valerie A. Arboleda

22 December 2014
Verified
Book Chapter
Closed access
PDF file
JPJeff S. Piotrowski
Jeff S. Piotrowski
SSScott W. Simpkins
Scott W. Simpkins
SLSheena C. Li
Sheena C. Li
RDRaamesh Deshpande
Raamesh Deshpande
SMSean J. McIlwain
Sean J. McIlwain
RARaymond J. Andersen
Raymond J. Andersen

6 August 2020 in medRxiv
Verified
Preprint
Open access
PDF file
JBJoshua S. Bloom
Joshua S. Bloom
EJEric M. Jones
Eric M. Jones
MGMolly Gasperini
Molly Gasperini
NLNathan B. Lubock
Nathan B. Lubock
LSLaila Sathe
Laila Sathe
VAValerie A. Arboleda
Valerie A. Arboleda
The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is due to the high rates of transmission by individuals who are asymptomatic at the time of transmission 1, 2 . Frequent, widespread testing of the asymptomatic population for SARS-CoV-2 is essential to suppress viral transmission. Despite increases in testing capacity, multiple challenges remain in deploying traditional reverse transcription and quantitative PCR (RT-qPCR) tests at the scale required for population screening of asymptomatic individuals. We have developed SwabSeq, a high-throughput testing platform for SARS-CoV-2 that uses next-generation sequencing as a readout. SwabSeq employs sample-specific molecular barcodes to enable thousands of samples to be combined and simultaneously analyzed for the presence or absence of SARS-CoV-2 in a single run. Importantly, SwabSeq incorporates an in vitro RNA standard that mimics the viral amplicon, but can be distinguished by sequencing. This standard allows for end-point rather than quantitative PCR, improves quantitation, reduces requirements for automation and sample-to-sample normalization, enables purification-free detection, and gives better ability to call true negatives. After setting up SwabSeq in a high-complexity CLIA laboratory, we performed more than 80,000 tests for COVID-19 in less than two months, confirming in a real world setting that SwabSeq inexpensively delivers highly sensitive and specific results at scale, with a turn-around of less than 24 hours. Our clinical laboratory uses SwabSeq to test both nasal and saliva samples without RNA extraction, while maintaining analytical sensitivity comparable to or better than traditional RT-qPCR tests. Moving forward, SwabSeq can rapidly scale up testing to mitigate devastating spread of novel pathogens.

1 December 2010 in Journal of Chromatography A
Verified
Journal Article
Closed access
SSScott W. Simpkins
Scott W. Simpkins
JBJeremy W. Bedard
Jeremy W. Bedard
SGStephen R. Groskreutz
Stephen R. Groskreutz
MSMichael M. Swenson
Michael M. Swenson
TLTomas E. Liskutin
Tomas E. Liskutin
DSDwight R. Stoll
Dwight R. Stoll

11 January 2019 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
SSScott W. Simpkins
Scott W. Simpkins
RDRaamesh Deshpande
Raamesh Deshpande
JNJustin Nelson
Justin Nelson
SLSheena C. Li
Sheena C. Li
JPJeff S. Piotrowski
Jeff S. Piotrowski
CMChad L. Myers
Chad L. Myers